Bajaj Healthcare Limited, a leading pharmaceutical company, has entered into a definitive Contract Development and Manufacturing Organization (CDMO) agreement with UK/EU-based companies for the development and manufacturing of 15 new Active Pharmaceutical Ingredients (APIs). This addition complements the company’s earlier contract with UK/EU clients for 15 molecules announced on 27th February 2024.
The new API pipeline includes a mix of off-patent generic APIs and APIs still under patent. This expansion highlights Bajaj Healthcare’s focus on strengthening its Research & Development capabilities, particularly in developing cost-effective synthesis routes. The company plans to further expand its manufacturing capabilities at its USFDA, EU, and TGA-approved site in Vadodara, Gujarat.
Mr. Anil Jain, Managing Director of Bajaj Healthcare, expressed his excitement about the company’s expanding reach and its potential to enter future CDMO deals in regions such as Australia, New Zealand, and South Africa, following the approval of their site by the TGA.
